首页> 外文期刊>Experimental and clinical transplantation >First Biventricular Jarvik 2000 Implants (Retroauricular Version) Via a Median Sternotomy
【24h】

First Biventricular Jarvik 2000 Implants (Retroauricular Version) Via a Median Sternotomy

机译:通过中位胸骨切开术首次植入双室Jarvik 2000植入物(耳廓式)

获取原文
           

摘要

Objectives: Organ shortages and increased numbers of nontransplant older patients have necessitated a search for alternatives to heart transplants. The Jarvik 2000 assist device (Jarvik Heart, Inc., Manhattan, NY, USA), as a small long-term axial flow pump, offers many advantages, such as retroauricular power supply, which minimizes driveline infection risks. When implanted biventricularly, the device may offer support for patients with biventricular heart failure, especially for nontransplant patients as a destination therapy. Materials and Methods: We implanted biventricular Jarvik 2000 systems into 3 men (aged, 65.3 ± 5.0 y; ejection fraction, 24.7% ± 1.5% for left ventricle and 17.7% ± 5.0% for right ventricle). These were the first patients worldwide to receive a biventricular Jarvik 2000 device with retroauricular power supply via a median sternotomy and with additional cardiac surgical procedures. Results: No technical problems were noted during biventricular assist device implant. Mean support time on the device was 224 ± 198 days. All 3 patients showed sufficient cardiac support; 2 patients died from noncardiac complications. Patient 1 died on day 3 as a result of postoperative hepatic failure after preo-perative reanimation, and patient 3 died as a result of an ileus and colon perforation after 50 days. Patient 2 died of ventricular fibrillation (after 1.5 y), which occurred 1 year after right ventricular pump shutdown, although significant improvement of right ventricle fun-ction was shown (ejection fraction increased by 48%). Conclusions: Our 3 patients were old, had multiple comorbidities, and needed further cardiac surgery. None of the patients died as a result of technical failure of the device but because of complications accompanying their morbidities. If complication rates can be reduced, a biventricular assist device implant could and should be considered as a potential alternative for nontransplant patients.
机译:目标:器官短缺和不移植的老年患者数量增加,因此必须寻找替代心脏移植的替代方法。 Jarvik 2000辅助设备(Jarvik Heart,Inc。,曼哈顿,纽约,美国)作为小型长期轴流泵,具有许多优势,例如耳后电源,可最大程度地减少传动系统感染的风险。当植入双心室时,该设备可以为双心室心力衰竭患者提供支持,尤其是作为目标疗法的非移植患者。材料和方法:我们将双心室Jarvik 2000系统植入3名男性(年龄为65.3±5.0 y;射血分数,左心室为24.7%±1.5%,右心室为17.7%±5.0%)。这些是全球首例接受双心室Jarvik 2000装置的患者,该装置通过正中胸骨切开术并通过额外的心脏外科手术获得耳后电源。结果:双心室辅助装置植入期间未发现技术问题。设备上的平均支持时间为224±198天。 3例患者均表现出足够的心脏支持; 2例患者死于非心脏并发症。患者1在术前复活后因肝功能衰竭而在第3天死亡,患者3在50天后因肠梗阻和结肠穿孔而死亡。患者2因右室泵关闭1年后发生的室颤(1.5 y)死亡,尽管右室功能明显改善(射血分数增加了48%)。结论:我们的3例患者年龄大,有多种合并症,需要进一步的心脏手术。没有一例患者死于该装置的技术故障,而是由于其并发症引起的并发症。如果可以降低并发症发生率,则可以并且应该考虑将双心室辅助装置植入物作为非移植物患者的潜在选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号